Based on the subgroup analyses, neoadjuvant immunotherapy may have advantages over perioperative immunotherapy in PD-L1 high-expression patients, non-squamous cell carcinoma patients as well as non-smoking patients. Here, CD274 is linked to squamous cell carcinoma.